Adi Mor, PhD

Chief Executive Officer and Chief Scientific Officer

Dr. Mor co-founded Chemomab in 2011. She has extensive knowledge and experience in immunology focusing on autoimmune and inflammatory diseases and broad experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor earned her PhD in immunology from Tel Aviv University in the Department of Neurobiochemistry and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.

 

 

Sigal Fattal, CPA, MBA

Chief Financial Officer

Ms. Fattal joined Chemomab in 2020. Ms. Fattal has a track record of over 20 years of extensive experience in leading IPOs, private investment, and M&A transactions, as well as establishing and managing effective financial, operational, and business activities in a vast range of industries. Ms. Fattal professional experience includes CFO positions at biotechnology companies, such as BiomX (NYSE: PHGE) and Evogene (NASDAQ: EVGN) (TASE: EVGN.TA).  Ms. Fattal holds a BA in Accounting and Economics, with honors, and an MBA, both from Tel Aviv University.

Arnon Aharon, MD

Chief Medical Officer

Dr. Aharon joined Chemomab in 2016 as Head of Clinical Development. Prior to Chemomab, Dr. Aharon served as Chief Medical Officer at BioLineRx Ltd. (NASDAQ/TASE: BLRX), where he directed the development pipeline for oncology and immunology. Dr. Aharon’s professional experience includes multiple senior management positions at biotechnology companies, such as Pharmos Ltd. (NASDAQ/TASE: PARX), Thrombotech Ltd., and LycoRed Ltd. Dr. Aharon is a member of several industry advisory groups and provides consulting services to biotechnology companies and academic institutions. Dr. Aharon earned his MD from the University of Tel Aviv, Israel, and has experience in internal medicine.

 

 

Sharon Elkobi, MSc, MBA

VP of Business Development

Mr. Elkobi joined Chemomab in 2019 with over 12 years of experience. Prior to joining Chemomab, Mr. Elkobi served as VP of Business Development at Neurim Pharmaceuticals Ltd. and as part of the senior leadership team, led the commercialization of Slenyto, the world’s first approved sleep drug for children with autism spectrum disorder and successfully signed multiple strategic global license and co-development deals. Prior to Neurim, Mr. Elkobi held a series of business development, sales and marketing positions at Medison Pharma Ltd., and at Teva Pharmaceuticals. Mr. Elkobi earned both his MSc in biochemistry and biotechnology and MBA from Tel Aviv University.

 

 

Michal Segal-Salto, PhD

VP of Research and Development

Joining Chemomab in 2015, Dr. Segal-Salto has over 15 years of experience in cell biology, molecular biology and biochemistry. She was awarded her PhD from the Weizmann Institute of Science in Rehovot, Israel. Dr. Segal-Salto has been successfully leading the R&D team since early preclinical stages through clinical translation.

 

 

 

Sharon Hashmueli, PhD

CMC and Regulatory Affairs

Dr. Hashmueli joined Chemomab in 2016 as Head of Chemistry, Manufacturing and Controls and Regulatory Affairs, with over 15 years of experience in drug development. Prior to joining Chemomab, Dr. Hashmueli worked at cCAM Biotherapeutics (acquired by Merck in 2015), developing a novel immune checkpoint inhibitor for cancer, and at Protalix Biotherapeutics, where she played a significant role in the development of Elelyso, an FDA approved treatment (marketed by Pfizer) for Gaucher disease. Dr. Hashmueli holds a PhD in biotechnology and food engineering from the Technion – Israel Institute of Technology.